维普中文期刊产品整合服务

Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: An open-label study

查看全文 作　　者：Laurent Peyrin-[1]Biroulet;Cécile [1]Laclotte;Xavier [2]Roblin;Marc-André [1]Bigard 高影响力作者 机构地区：[1]Department of Hepato-Gastroenterology, University Hospital of Nancy, Vandoeuvre-les-Nancy, France;[2]Department of Hepato-Gastroenterology, University Hospital of Grenoble, La Tronche, France高影响力机构 出　　处：《World Journal of Gastroenterology》索引2007年第13卷第16期,共5页高影响力期刊 摘　　要：AIM: To evaluate the efficacy of adalimumab induction therapy in patients with ulcerative colitis who previously responded to infliximab and then lost response or became intolerant. METHODS: Ten patients with ulcerative colitis were enrolled in a 4-wk open-label trial. The patients received a loading dose of 160 mg adalimumab at wk 0 followed by 80 mg at wk 2. The primary efficacy measure was clinical improvement at wk 4, as defined by a decrease in clinical activity index (CAI) of more than 4. RESULTS: Four of 10 patients (40%) benefited from subsequent adalimumab therapy; one patient achieved remission (CAI < 4) and 3 had clinical improvement at wk 4. 6 patients had no response (60%); 2 of 6 (33.3%) subsequently underwent colectomy. This was accompanied by a decrease in median CRP concentration from 16.8 mg/mL at baseline to 3.85 mg/mL at wk 4, excluding two patients who underwent colectomy after two infusions of adalimumab. Among the 6 patients with severe colitis (CAI > 12) at baseline, none achieved remission and only one patient had clinical improvement at wk 4. CONCLUSION: The small advantage of adalimumab in patients with mild to moderate ulcerative colitis and lost response or intolerance to infliximab needs to be confirmed in randomised, double-blind, placebo- controlled trials. 关 键 词：溃疡性结肠炎 英夫利昔单抗 治疗 阿达木单抗 药物不耐性
相关文献

参考文献(21)

引证文献(2)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费